32 results about "Nephrotic syndrome" patented technology

The invention discloses a biomarker for nephrotic syndrome, an analysis method and a kit, which can be effectively used for diagnosis of nephrotic syndrome and have high sensitivity and accurate and reliable results. The biomarker for nephrotic syndrome comprises the mRNA, the protein and the enzymatic activity level of the following substances: lactate dehydrogenase B.

The present invention belongs to the field of traditional Chinese medicines, and particularly relates to Leixihaokang, a preparation method therefor, and use thereof. The Leixihaokang of the present invention is prepared from the following active pharmaceutical ingredients in parts by weight: 10 parts of Tripterygium glycosides and 0.1-1.3 parts of Artemisia annua extract. According to the present invention, animal experiments prove that the Leixihaokang can ameliorate renal damage in nephrotic syndrome caused by adriamycin, reduce the occurrence of proteinuria, and reduce the apoptosis of renal tissue cells. Meanwhile, the Leixihaokang of the present invention has a good inhibitory effect on renal, hepatic, splenic, and cardiac toxicity in the treatment process of nephrotic syndrome. According to the present invention, animal experiments also prove that the Leixihaokang can ameliorate skin injury in imiquimod-induced psoriasis, reduce inflammatory infiltration and alleviate skin damage. Meanwhile, the Leixihaokang has a certain degree of inhibitory effect on the hepatic and reproductive system toxicity in the treatment process of psoriasis.

The present invention provides an adeno-associated virus (AAV) vector gene therapy for use in treating a monogenic form of nephrotic syndrome, wherein the AAV vector comprises a NS-associated transgene and minimal nephrin promoter NPHIS1 or podocin promoter NPHIS2.

This invention provides a kit for detecting anti-peroxidase-1-IgG antibodies, comprising the antigen protein peroxiredoxin-1 (peroxidase-1), a solid-phase carrier, labeled antibody, antigen dilution buffer, sample dilution buffer, antibody dilution buffer, substrate chromogenic agent, washing buffer, standards, positive control, and negative control. This kit utilizes an indirect reaction principle combined with magnetic microparticle chemiluminescence immunoassay to detect anti-peroxidase-1-IgG antibodies in the serum of the test sample. This invention is the first to identify autoantibodies against the target antigen peroxidase-1 in the serum of patients with autoimmune nephrotic syndrome. The provided kit provides a basis for domestic and international research on the molecular mechanisms and clinical diagnosis and treatment of autoimmune nephrotic syndrome related to peroxidase-1 and peroxidase-1-IgG autoantibodies.

A method of treating nephrotic syndrome (NS) in a subject is described. The method includes administering a therapeutically effective amount of a PPARγ agonist to the subject.

The present invention provides a kit for detecting antigen myosin 1 IgG antibodies, which is composed of antigen protein Tropomyosin 1 (tropomyosin 1), a solid phase carrier, a standard, a positive quality control product, a negative quality control product, a labeled antibody, a substrate color developing solution, an antibody diluent, an antigen diluent, a sample dilution buffer, a washing solution, a stop solution, etc. The present invention utilizes the target antigen Tropomyosin 1 corresponding to the anti-Tropomyosin 1 IgG antibody, and uses human anti-label peptide IgG as a standard for quantitative detection to perform anti-Tropomyosin 1 IgG antibody detection on the antigen-antibody complex formed in the serum. The kit of the present invention is easy to operate, has very good reagent stability, is easy to store, and fills the gap in identifying biomarkers for patients with immune nephrotic syndrome at home and abroad.

The present application relates to the technical field of oyster peptides, and specifically to a method for preparing oyster peptides and their use in improving male reproductive function. The present application utilizes oyster peptides as raw materials, grafts oleanolic acid saponins thereon, and composites them with chitosan to prepare an emulsion of a ternary complex. The emulsion can form stable microscopic particles and has stable rheological properties. Through simulated digestion experiments, it was found that the emulsion has a sustained-release effect on the digestion of oyster peptides, and can at least reduce the proportion of digestion in the oral cavity. In addition, the use of the emulsion and the oyster peptide to intervene in rats with nephrotic syndrome can effectively alleviate their nephrotic syndrome, and at the same time promote the male sexual function of rats, and has an application prospect of modifying and improving male reproductive function.

1. Name of the product in this design: Treatment cart (for rehabilitation treatment of children with nephrotic syndrome). 2. Purpose of this design: For use in the rehabilitation treatment of sick children. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: 3D view 1.

An object of the present invention is to provide a method capable of detecting whether a subject has systemic lupus erythematosus (preferably nephrotic syndrome) with high accuracy without performing a renal biopsy, a biomarker for carrying out such detection, and the like. The concentration of 3′,4′-didehydro-3′-deoxycytidine in urine collected from a test subject is measured, and this concentration is compared with a reference concentration for control, which allows to detect whether the above-mentioned test subject has systemic lupus erythematosus (preferably lupus nephritis) with high accuracy.

The present invention provides an adeno-associated virus (AAV) vector gene therapy for use in treating a monogenic form of nephrotic syndrome, wherein the AAV vector comprises a NS-associated transgene and minimal nephrin promoter NPHS1 or podocin promoter NPHS2.

The invention relates to an anti-CD45RO monoclonal antibody and application thereof in preparation of drugs for treating autoimmune diseases, the anti-CD45RO monoclonal antibody comprises an antibody heavy chain variable region and / or an antibody light chain variable region: a) the antibody heavy chain variable region comprises three complementary determining regions: CDR1, CDR2 and CDR3; and b) an antibody light chain variable region, wherein the antibody light chain variable region comprises complementarity determining regions: L-CDR1, L-CDR2 and L-CDR3. The invention also comprises application of the anti-CD45RO monoclonal antibody in preparation of drugs for treating immune diseases. The monoclonal antibody aiming at the CD45RO can specifically recognize and combine CD45RO molecules on the surfaces of the memory T cells, so that the activation and function of the memory T cells are blocked, and the inflammatory response of immune diseases is reduced by reducing the activity of the memory T cells, so that the symptoms of patients are improved. The compound is expected to be used for preparing medicines for treating immune diseases such as nephrotic syndrome.

The application discloses a chemical structural formula of a biphenyl sulfonamide compound of a bis-benzimidazole, and also discloses application of the compound in preparation of a pharmaceutically acceptable salt or solvate, application of the compound and the pharmaceutically acceptable salt or solvate in preparation of a medicine for treating endothelin-dependent or angiotensin II-dependent diseases. Meanwhile, the biphenyl sulfonamide compound of the bis-benzimidazole can also be used in combination by changing substituted functional groups. The biphenyl sulfonamide compound of the bis-benzimidazole, the prepared pharmaceutically acceptable salt or solvate and the medicine prepared by the compound have pharmacological activities, and have pharmacological effects in animals including human beings, and are particularly useful in treatment or prevention of IgA nephropathy, focal segmental glomerulosclerosis, nephrotic syndrome, chronic kidney disease, diabetic nephropathy, hypertension, coronary heart disease and myocardial infarction.

The present invention provides a kit for detecting anti-filamentous actin capping protein β-IgG antibodies, which is composed of an antigen protein, filamentous actin capping protein β (F-actin-capping protein subunit beta), a solid-phase carrier, a labeled antibody, an antigen diluent, a sample dilution buffer, an antibody diluent, a substrate chromogenic agent, a washing solution, a standard product, a positive control product, and a negative control product. The anti-filamentous actin capping protein β-IgG autoantibodies are detected by a specific kit. The present invention for the first time identifies autoantibodies against the target antigen, filamentous actin capping protein β, and provides a detection kit for such autoantibodies. The kit provided by the present invention provides a basis for the research on the molecular mechanism and clinical diagnosis and treatment of autoimmune nephrotic syndrome related to filamentous actin capping protein β and anti-filamentous actin capping protein β-IgG autoantibodies at home and abroad.

The application discloses a method for constructing a rat passive Heymann nephritis model, and belongs to the technical field of biological medicines, and comprises the following steps: injecting a rat with Sheep Anti-Rat Fx1A Serum through a tail vein for multiple times with an interval of 24 hours. The rat PHN model is successfully constructed by twice tail vein injection of the rat with the Sheep Anti-Rat Fx1A Serum, the model rat shows the nephrotic syndrome characterized by a large amount of proteinuria, the disease course is long, the disease condition is not easy to relieve, and the long-term observation requirement can be met. The modeling method is simple and easy to realize, and can provide research help for dynamic observation of kidney damage of the model animal, discussion of the pathogenesis of the PHN and research and development of drug treatment of the human model nephropathy.

The present invention provides a kit for detecting anti-serine / arginine-rich splicing factor 9-IgG antibodies, which consists of an antigen protein rich in serine / arginine splicing factor 9, a solid phase carrier, a labeled antibody, an antigen diluent, a sample dilution buffer, an antibody diluent, a substrate color developer, a washing solution, a standard substance, a positive quality control product, and a negative quality control product. Anti-serine / arginine-rich splicing factor 9-IgG autoantibodies are detected by a specific kit. The present invention identifies autoantibodies against the target antigen rich in serine / arginine splicing factor 9 for the first time, and provides a detection kit for the autoantibodies. The kit provided by the present invention provides a basis for the molecular mechanism research and clinical diagnosis and treatment of autoimmune nephrotic syndrome related to serine / arginine-rich splicing factor 9 and serine / arginine-rich splicing factor 9-IgG autoantibodies at home and abroad.

The present invention provides a kind of detection kit for detecting anti-aconitate hydratase IgG antibodies, by aconitate hydratase (aconitate hydratase) antigen protein, labeled antibody liquid, the solid phase carrier coated with aconitate hydratase antigen, sample diluent, antibody and antigen diluent, substrate color developing solution, washing solution, stop solution, standard substance, positive and negative quality control product composition. The present invention is through the contact of the serum sample being tested with the target antigen aconitate hydratase polypeptide or its binding fragment, an immune reaction occurs, an antigen-antibody complex is formed, and the antigen-antibody complex formed is tested for anti-aconitate hydratase IgG autoantibodies. The present invention identifies for anti-aconitate hydratase IgG antibodies for the first time, and provides a better detection method for the identification of autoimmune nephrotic syndrome related to anti-aconitate hydratase IgG antibodies at home and abroad.

The application belongs to the technical field of nephropathy diagnosis medicine or reagent, and particularly relates to application of multiple groups of metabolic markers in differential diagnosis of different pathological types of nephrotic syndrome. The multiple groups of metabolic markers for diagnosing different pathological types of nephrotic syndrome (including membranous nephropathy and minimal change nephropathy) are provided, and the existing diagnosis means cannot realize non-invasive, rapid and effective pathological type differential diagnosis of primary nephrotic syndrome. The markers include markers for diagnosing membranous nephropathy and / or markers for diagnosing minimal change nephropathy. The markers can be used for preparing differential diagnosis products of different pathological types of nephrotic syndrome, the sample of a subject is pretreated, the level of the marker in the sample is determined and analyzed, the type of nephropathy of the subject is diagnosed, and the application has important clinical application value.

Hydantoin based compounds of formula (I) useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

Provided is a use of ephrin-B as a marker for assisting in the diagnosis of nephrotic syndrome. A nephrotic syndrome testing method comprises a step for measuring the level of expression of ephrin-B in the urine of a subject. A reagent for nephrotic syndrome diagnosis includes a substance that specifically binds to ephrin-B.

The application provides a preparation method of total saponins of Radix Fritillariae Thunbergii, which comprises the following steps: adding Radix Fritillariae Thunbergii into ethanol to extract, and then concentrating under reduced pressure to obtain a crude extract; dissolving the crude extract in water, and then adsorbing the water on macroporous adsorption resin, and then eluting the macroporous adsorption resin with water and ethanol; collecting the ethanol eluate, and then concentrating under reduced pressure to obtain component 1; dissolving the component 1 in water, and then extracting with an organic solvent; and drying the water phase obtained by extraction under reduced pressure to obtain the total saponins of Radix Fritillariae Thunbergii. The application optimizes the extraction and purification method of the total saponins of Radix Fritillariae Thunbergii to a certain extent, shortens the preparation time of the total saponins, improves the content of the total saponins, and proves through experimental research that the total saponins of Radix Fritillariae Thunbergii can treat the nephrotic syndrome caused by adriamycin (ADR), improve the glomerular filtration rate, reduce the glomerular inflammation, and has a significant protective effect on the kidney.

The invention discloses a traditional Chinese medicine compound preparation for treating nephrotic syndrome and a preparation method of the traditional Chinese medicine compound preparation, and belongs to the technical field of nephrotic syndrome treatment.The synbiotic microcapsule is prepared by compatibility of traditional Chinese medicines such as safflower, scutellaria baicalensis and perilla frutescens, and the synbiotic microcapsule is prepared by embedding traditional Chinese medicine extracts such as astragalus membranaceus and lily with lactobacillus acidophilus and bifidobacterium; and the wall material is prepared from mannose grafted meadowfoam seed extract, sodium alginate and fucoidin sulfate. The synbiotics microcapsule utilizes a Maillard reaction modified wall material to enhance gastric acid erosion resistance, realizes intestinal targeted colonization through mannose residues, protects probiotics, directionally releases traditional Chinese medicine active components, adjusts intestinal flora balance and inhibits uremia toxin generation. The traditional Chinese medicine components such as the safflower and the scutellaria baicalensis improve kidney blood circulation, relieve inflammatory response and regulate lipid metabolism by inhibiting an NF-kappa B channel, activating an AMPK channel and the like; the components such as the Chinese yam and the Chinese wolfberry can repair the permeability of glomerular basement membrane and improve the hypoproteinemia.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and particularly to the application of TCM compositions in the preparation of drugs for the prevention and treatment of nephrotic syndrome. The TCM composition of this invention includes *Sedum sarmentosum*, seaweed, oyster shell, hawthorn, *Siegesbeckia orientalis*, *Schisandra chinensis*, and *Polygonum cuspidatum*. This invention has found that this composition can significantly reduce urinary protein levels, regulate serum ALB, Cr, and BUN levels, improve renal function, and has a good therapeutic effect on nephrotic syndrome. Moreover, this TCM composition is an existing prepared Chinese medicine, safe to use, and its preparation method is simple, rapid, efficient, and easy to operate. The prepared mixtures, tablets, capsules, and micro-pellets are easy to carry and convenient to take.

The present invention provides an adeno-associated virus (AAV) vector gene therapy for use in the treatment of nephrotic syndrome in a single gene form wherein the AAV vector comprises an NS-related transgene and a minimum nephrin promoter NPHS1 or a podocin promoter NPHS2.

The present invention provides a kit for detecting anti-vinculin-IgG antibodies, which consists of an antigen protein Vinculin (vinculin), a solid phase carrier, a labeled antibody, an antigen diluent, a sample dilution buffer, an antibody diluent, a substrate color developer, a washing solution, a standard substance, a positive quality control substance, and a negative quality control substance. The kit of the present invention utilizes the indirect reaction principle combined with magnetic particle chemiluminescence immunoassay to detect anti-Vinculin-IgG antibodies in a sample to be tested. The present invention identifies for the first time autoantibodies against the target antigen Vinculin in the serum of patients with autoimmune nephrotic syndrome, and provides a detection kit for the autoantibodies. The kit provided by the present invention provides a basis for the molecular mechanism research and clinical diagnosis and treatment of autoimmune nephrotic syndrome related to Vinculin and Vinculin-IgG autoantibodies at home and abroad.

The invention provides an application of glutamine in treatment of primary nephrotic syndrome and an application thereof, and particularly relates to an application of a combination of glutamine or a derivative thereof or glutamine guat acid sodium and prednisone acetate in preparation of a medicine, and the medicine is used for preventing, relieving and / or treating the primary nephrotic syndrome. According to the application disclosed by the invention, the glutamine or the derivative thereof and the prednisone acetate are combined for use, so that the negative conversion time of the primary nephrotic syndrome can be effectively shortened, the times of later recurrence and infection are reduced, the prognosis effect is improved, and a new thought is provided for preventing, relieving and / or treating the primary nephrotic syndrome.

The present invention provides an adeno-associated virus (AAV) vector gene therapy for use in treating a monogenic form of nephrotic syndrome, wherein the AAV vector comprises a NS-associated transgene and minimal nephrin promoter NPHS1 or podocin promoter NPHS2.

The application discloses a midstream urine collection and analysis device for nephrotic syndrome patients and belongs to the field of medical urine detection instruments. The device comprises a support, a midstream urine storage bin, an initial and final urine storage bin, a switching device, a floating trigger mechanism, a tension sensor, a controller, a pneumatic cylinder and a test paper clamping device integrated in the midstream urine storage bin. The floating trigger mechanism detects the initial urine volume, and the signal is transmitted through the tension sensor to control the pneumatic cylinder to drive the switching plate to slide, so that the urine flow channel is automatically switched, and the initial, midstream and final urine is stored in different bins. The test paper clamping device is divided into a test paper bearing mechanism and a pressing type test paper taking and placing mechanism. The application realizes automatic urine segmentation and collection, has high sampling standardization, reduces urine pollution and detection errors, is suitable for long-term and multiple urine routine detection of nephrotic syndrome patients, has a structure easy to clean and high automation, and is suitable for clinical popularization and use.

The invention belongs to the field of traditional Chinese medicine, and particularly relates to rayleikang and a preparation method and application thereof. The rayleikang provided by the invention is prepared from the following raw material medicines in parts by weight: 10 parts of tripterygium glycosides and 0.1-1.3 parts of an artemisia annua extract. Animal experiments prove that the rayenkam can improve kidney injury of the nephrotic syndrome caused by adriamycin, reduce generation of proteinuria and reduce apoptosis of kidney tissue cells, and meanwhile, the rayenkam has a good inhibition effect on kidney, liver and cardiac toxicity occurring in the treatment process of the nephrotic syndrome. Animal experiments also prove that the rareenkam can improve skin injury of psoriasis induced by imiquimod, reduce inflammation infiltration and relieve skin lesion, and meanwhile, the rareenkam has a certain degree of inhibiting effect on liver and reproductive system toxicity occurring in the psoriasis treatment process.

The present invention provides a kit for detecting anti-proteasome subunit alpha 1-IgG antibody, which is composed of antigen protein Proteasome subunit alpha type 1 (proteasome subunit alpha 1), solid phase carrier, labeled antibody, antigen and antibody diluent, sample dilution buffer, substrate chromogenic agent, washing solution, standard product, positive and negative quality control products. The kit of the present invention utilizes the reaction principle of indirect method combined with magnetic particle chemiluminescence immunoassay to detect anti-proteasome subunit alpha 1-IgG antibody in the serum to be detected. The present invention first identifies the autoantibody against the target antigen proteasome subunit alpha 1 in the serum of patients with autoimmune nephrotic syndrome. The present invention provides a basis for the research on the molecular mechanism and clinical diagnosis and treatment of autoimmune nephrotic syndrome related to proteasome subunit alpha 1 and proteasome subunit alpha 1-IgG autoantibody at home and abroad.